Stratos Wealth Advisors LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stratos Wealth Advisors LLC lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 8,581 shares of the biopharmaceutical company’s stock after selling 67 shares during the quarter. Stratos Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $6,113,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Rakuten Securities Inc. lifted its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $37,000. Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. Finally, Valley Wealth Managers Inc. purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $49,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 4.5 %

Regeneron Pharmaceuticals stock opened at $697.05 on Wednesday. The firm has a market cap of $76.60 billion, a PE ratio of 17.25, a P/E/G ratio of 1.60 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm’s 50 day moving average price is $719.16 and its two-hundred day moving average price is $918.90. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the business earned $11.86 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.50%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Leerink Partners lowered their target price on Regeneron Pharmaceuticals from $980.00 to $862.00 and set a “market perform” rating on the stock in a report on Tuesday. Finally, Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $983.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.